NCT00652431已完成1 期
SCH 465981: Assessment of Bi-Directional Interaction Between Components of Vytorin® (Ezetimibe and Simvastatin) and Niaspan® (Niacin Extended-Release Tablets) in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 主要终点
- Evaluate the potential for a PK interaction between NIASPAN and components of VYTORIN, using Tmax, Cmax, and AUC.
研究概览
简要总结
This is a single-center, randomized, open-label, 3-period, 3-treatment multiple-dose crossover study designed to assess the interaction between VYTORIN® (Ezetimibe and Simvastatin) and NIASPAN® (Niacin Extended-Release Tablets) in healthy subjects. Treatment spans 7 days
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject must meet ALL the criteria listed below for entry:
- •Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules.
- •Subjects of either sex and of any race between the ages of 18 and 55 years, inclusive, having a Body Mass Index (BMI) between 19 to 32, inclusive. BMI = weight (kg)/height (m^2).
- •Subjects' clinical laboratory tests (CBC, blood chemistry, and urinalysis) must be within normal limits or clinically acceptable to the investigator/sponsor. Subject's liver function test results (AST, ALT, and GGT) must not be elevated above normal limits at Screening and on Day-
- •Subjects' CPK test results must not be elevated more than 1.25 times the upper limit of normal, at Screening and on Day -
- •Subjects must be free of any clinically significant disease that would interfere with the study evaluations.
- •Screening ECG conduction intervals must be within gender specific normal range (QTc males <=430 msec and females <=450 msec).
- •Vital sign measurements (taken after ~3 minutes in a seated position) must be within the following ranges:
- •oral body temperature between 35.0°C to 37.5°C
- •systolic blood pressure, 90 to 140 mm Hg
- •diastolic blood pressure, 45 to 90 mm Hg
- •pulse rate, 40 to 100 bpm
- •Female subjects of childbearing potential must have a negative serum pregnancy test (beta-hCG) at Screening and have a negative urine pregnancy test upon each admission to the study center.
- •Women of child-bearing potential must agree to use medically accepted methods of contraception prior to screening, while receiving protocol-specified medication, and for 30 days after stopping the medication. Acceptable methods of contraception include:
- •Condoms (male or female) with spermicide,
- •Diaphragm or cervical cap with spermicide
- •Medically prescribed IUD with spermicide, and
- •Surgical sterilization (eg. hysterectomy or tubal ligation). Vasectomy of the partner should be considered a single barrier and one additional contraceptive methods listed above must be used. Females who are not currently sexually active must agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the study.
- •Female subjects must be surgically sterilized (eg, documented hysterectomy or tubal ligation) or be postmenopausal. (Defined as 12 months with no menses and with an estradiol level of <30 pg/mL.)
- •Men must agree to use a medically accepted method of contraception prior to Screening, while receiving protocol-specified medication, and for 30 days after stopping the medication.
排除标准
- •The subject will be excluded from entry if ANY of the criteria listed below are met:
- •Female subjects who are pregnant, intend to become pregnant (within 3 months of ending the study), or are breastfeeding.
- •Subjects who, in the opinion of the investigator, will not be able to participate optimally in the study.
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following and be discussed with the sponsor prior to enrollment into the trial:
- •history or presence of inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding;
- •history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
- •history of pancreatic injury or pancreatitis;
- •history or presence of liver disease or liver injury;
- •history or presence of impaired renal function as indicated by abnormal creatinine, urinary albumin, BUN/urea or clinical significant urinary cellular constituents (eg, cast); or
- •history of urinary obstruction or difficulty in voiding.
- •Subject who has a history of any infectious disease within 4 weeks prior to drug administration.
- •Subjects who are positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
- •Subjects who have a positive screen for drugs with a high potential for abuse.
- •Subjects with a history of mental instability or who have been treated for mood disorders.
- •Subjects with a history of alcohol or drug abuse in the past 2 years.
- •Subjects who have donated blood in the past 60 days.
- •Subjects who have previously received and demonstrated intolerance to NIASPAN® (niacin extended-release tablets), VYTORIN® (ezetimibe/simvastatin), ZETIA® (ezetimibe), ZOCOR® (simvastatin) or products containing niacin/nicotinic acid.
- •Subjects who are currently participating in another clinical study or have participated in a clinical study within 30 days.
- •Subjects who are part of the study staff personnel or family members of the study staff personnel.
- •Subjects who have demonstrated allergic reactions (eg, food, drug, atopic reactions or asthmatic episodes).
- •Subjects who smoke more than 10 cigarettes or equivalent tobacco use per day.
- •Subjects who have received any treatment listed in Table 2 of protocol P04955 (Doc ID: 3498819) more recently than the indicated washout period prior to Baseline in each period.
- •Subjects who received vaccination(s) within 30 days prior to screening.
研究组 & 干预措施
Vytorin + Niaspan
Experimental
NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 + VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
干预措施: Vytorin + Niaspan (Drug)
Vytorin
Active Comparator
VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
干预措施: Vytorin (Drug)
Niaspan
Active Comparator
NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 for a total of 7 days of treatment
干预措施: Niaspan (Drug)
结局指标
主要结局
Evaluate the potential for a PK interaction between NIASPAN and components of VYTORIN, using Tmax, Cmax, and AUC.
时间窗: Day 7
次要结局
- Evaluate safety and tolerability: laboratory test results, ECGs, adverse events, vital signs.(throughout study)
研究者
相似试验
已完成
1 期
A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy ParticipantsHealthyNCT04090086Janssen Research & Development, LLC16
已完成
1 期
Radiotherapy & Combi in Metastatic MelanomaMetastatic MelanomaNCT02392871Melanoma and Skin Cancer Trials Limited10
已完成
1 期
A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819Healthy VolunteerNCT01409369Hoffmann-La Roche26
已完成
1 期
DDI Study to Investigate Interaction Between Amikacin and POL7080HealthyNCT02897869Polyphor Ltd.14
已完成
1 期
Bio-equivalence Study Between SAPHRIS and AsenapineBipolar DisorderSchizophreniaNCT01948024Sun Pharmaceutical Industries Limited65